Biomarker Discovery May Lead to New Treatments for People with ALS

Researchers have discovered that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. This finding could lead to a new treatment for the debilitating neurological disease, which affects approximately 30,000 Americans.

Categories: Research News, Treatments  |  Tags: ALS, ALS community, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Brigham and Women’s Hospital, Harvard Medical School, Howard Weiner, Howard Weiner Robert L Kroc Professor of Neurology, Lou Gehrig's disease, Massachusetts General Hospital, Massachusetts General Hospital ALS Multidisciplinary Clinic, Merit Cudkowicz, monocytes biomarker ALS, Oleg Butovsky, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Robert L. Kroc Professor of Neurology, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, The Journal of Clinical Investigation  |  No comments